Implication of CD35, CD21 and CD55 in Exudative Age-related Macular Degeneration
This trial is active, not recruiting.
|Condition||age-related macular degeneration|
|Treatment||cd 35, cd21, cd55|
|Sponsor||Rudolf Foundation Clinic|
|Start date||September 2008|
|End date||December 2009|
|Trial size||120 participants|
|Trial identifier||NCT01174407, EK08010-VK|
The purpose of this study is to determine a possible implication of CD21, CD35 and CD55 in the pathogenesis of age-related macular degeneration. The aim is to asses a difference in expression rates of these factors on AMD-patients and a healthy control group.
|Observational model||case control|
determine a possible implication of CD21, CD35 and CD55 in the pathogenesis of age-related macular degeneration
time frame: 1 day
expression rates of on AMD-patients and a healthy control group
time frame: 1 year
Male or female participants at least 55 years old.
Inclusion Criteria: - Man and women over 18 years old - Filled out informed consent - Diagnosis of non-exudative/ exudative age related macular degeneneration Exclusion Criteria: - Inherited retinal diseases - Other acquired retinal/ macular - Missing informed consent
|Official title||Is CD35, CD21 and CD55 Associated With Exudative Age-related Macular Degeneration|
Call for more information